Company intelligence / Profile preview
Cleave Therapeutics
San Francisco, California, United Statescleavetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Advancing CB-5339, a second-generation small molecule VCP/p97 inhibitor, in clinical studies for acute myeloid leukemia (AML). The National Cancer Institute (NCI) is sponsoring and evaluating CB-5339 in clinical studies for patients with solid tumors[4].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
National Cancer Institute (NCI)
Beyond the preview
Go deeper on Cleave Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cleave Therapeutics.